Peptide database
Browse and explore comprehensive, sex-disaggregated peptide profiles.
The 2X Blend combines two complementary secretagogue research peptides, CJC-1295 (a GHRH analog) and Ipamorelin (a selective ghrelin/GHS-receptor agonist), in…
ACE-031 (ramatercept) is a soluble activin receptor type IIB–Fc fusion designed to inhibit myostatin signaling and increase muscle mass.
AICAR is an AMPK activator studied clinically as acadesine for cardioprotection (reaching Phase 3 in cardiac surgery) and preclinically as an 'exercise…
CJC-1295 with DAC is a long-acting GHRH analog whose drug-affinity-complex modification extends its half-life by binding serum albumin.
CJC-1295 without DAC (Modified GRF 1-29) is a short-acting growth-hormone-releasing hormone analog used as a tool compound in secretagogue research.
Follistatin-344 is an isoform of the natural myostatin/activin antagonist follistatin, studied preclinically (including via gene therapy) for muscle growth.
GDF-8, better known as myostatin, is an endogenous TGF-β-family protein that limits skeletal-muscle growth.
GHRP-2 (pralmorelin) is a growth-hormone secretagogue approved in Japan as a diagnostic agent for growth-hormone deficiency.
GHRP-6 is a growth-hormone secretagogue studied in human pharmacology for growth-hormone release and, more recently, tissue-protective effects.
Hexarelin is a synthetic growth-hormone secretagogue studied in short-term human pharmacology work on growth-hormone release and cardiovascular effects; it has…
IGF-1 DES is a truncated, more potent form of IGF-1 used mainly as a research reagent and, unapproved, for muscle growth.
IGF-1 LR3 is a long-acting IGF-1 analog used mainly as a cell-culture reagent and, unapproved, for muscle growth.
Ipamorelin is a selective growth-hormone secretagogue studied in early human and animal work.
MK-677 (ibutamoren) is an orally active ghrelin-receptor agonist that raises growth hormone and IGF-1.
Sermorelin is a synthetic fragment of growth-hormone-releasing hormone (GHRH 1-29) formerly FDA-approved as Geref for assessing growth-hormone deficiency…
About the peptide database
How many peptides are in the database?
The database indexes 91 research peptides, of which 82 have completed a full sex-disaggregated evidence review. The rest carry their research facts while the female-evidence review is written.
How is each peptide's evidence grade decided?
Every compound's A–E grade is derived from published study fields by a fixed, transparent rubric, not an opaque score. Grade A requires human evidence that included female subjects; grade E means anecdotal, in-vitro, or no indexed studies.
What does the female study count tell me?
It shows how many indexed studies included female subjects and, separately, how many reported outcomes by sex. Where no qualifying female study exists, the profile says "unstudied" rather than extrapolating from male data.
Can I search the database by symptom or goal?
Yes. Use the search box to match compound names, aliases, and research tags, or filter by research area such as hormonal, metabolic, skin, or recovery. Vera, the cited AI assistant, can also answer questions across the whole database.